These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3140158)

  • 1. Visual symptoms associated with the presence of a lupus anticoagulant.
    Levine SR; Crofts JW; Lesser GR; Floberg J; Welch KM
    Ophthalmology; 1988 May; 95(5):686-92. PubMed ID: 3140158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaso-occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy).
    Kleiner RC; Najarian LV; Schatten S; Jabs DA; Patz A; Kaplan HJ
    Ophthalmology; 1989 Jun; 96(6):896-904. PubMed ID: 2472589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central retinal-artery occlusion in a patient with circulating lupus anticoagulant.
    Reisin LH; Reisin I; Darawshi A; Aviel E
    Ann Ophthalmol; 1989 Jul; 21(7):269-71. PubMed ID: 2505658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.
    McHugh NJ; Moye DA; James IE; Sampson M; Maddison PJ
    Ann Rheum Dis; 1991 Aug; 50(8):548-52. PubMed ID: 1909518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lupus anticoagulant and retinal vaso-occlusive disease.
    Fitzpatrick EP; Chesen N; Rahn EK
    Ann Ophthalmol; 1990 Apr; 22(4):148-52. PubMed ID: 2112354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times.
    Alving BM; Barr CF; Tang DB
    Am J Med; 1990 Feb; 88(2):112-6. PubMed ID: 2105643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occlusion of small hepatic veins associated with systemic lupus erythematosus with the lupus anticoagulant and anti-cardiolipin antibody.
    Nakamura H; Uehara H; Okada T; Kambe H; Kimura Y; Ito H; Hayashi E; Yamamoto H; Kishimoto S
    Hepatogastroenterology; 1989 Oct; 36(5):393-7. PubMed ID: 2516008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.
    Derksen RH; Hasselaar P; Blokzijl L; Gmelig Meyling FH; De Groot PG
    Ann Rheum Dis; 1988 May; 47(5):364-71. PubMed ID: 3133992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticardiolipin antibodies: their presence as a marker for lupus anticoagulant in pregnancy.
    Pattison NS; McKay EJ; Liggins GC; Lubbe WF
    N Z Med J; 1987 Feb; 100(817):61-4. PubMed ID: 3103033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.
    Love PE; Santoro SA
    Ann Intern Med; 1990 May; 112(9):682-98. PubMed ID: 2110431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus anticoagulant. A report of 8 cases.
    Agarwal MB; Agarwal UM
    J Assoc Physicians India; 1991 Mar; 39(3):243-5. PubMed ID: 1908857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiphospholipid antibodies: clinical significance in systemic lupus erythematosus].
    Zhou DC; Dong Y; Pan JQ
    Zhonghua Nei Ke Za Zhi; 1989 Feb; 28(2):78-80, 125. PubMed ID: 2500316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
    Violi F; Ferro D; Valesini G; Quintarelli C; Saliola M; Grandilli MA; Balsano F
    BMJ; 1990 Apr; 300(6732):1099-102. PubMed ID: 2111722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population.
    Lockwood CJ; Romero R; Feinberg RF; Clyne LP; Coster B; Hobbins JC
    Am J Obstet Gynecol; 1989 Aug; 161(2):369-73. PubMed ID: 2504043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for thrombosis in lupus patients.
    Hasselaar P; Derksen RH; Blokzijl L; Hessing M; Nieuwenhuis HK; Bouma BN; De Groot PG
    Ann Rheum Dis; 1989 Nov; 48(11):933-40. PubMed ID: 2512863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post partum renal failure in systemic lupus erythematosus associated with circulating lupus anticoagulant and anticardiolipin antibody.
    Kincaid-Smith P
    Clin Nephrol; 1991 Jul; 36(1):52. PubMed ID: 1909612
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin.
    Rote NS; Dostal-Johnson D; Branch DW
    Am J Obstet Gynecol; 1990 Aug; 163(2):575-84. PubMed ID: 2117391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant.
    Pope JM; Canny CL; Bell DA
    Am J Med; 1991 Mar; 90(3):299-309. PubMed ID: 1900660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss.
    Creagh MD; Malia RG; Cooper SM; Smith AR; Duncan SL; Greaves M
    J Clin Pathol; 1991 Jan; 44(1):45-7. PubMed ID: 1900070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis.
    Canoso RT; de Oliveira RM
    Am J Hematol; 1988 Apr; 27(4):272-5. PubMed ID: 3128108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.